After more that 10 years at the firm, Susan Galbraith has taken on an expanded role heading up oncology R&D at AstraZeneca.
Following the death of José Baselga earlier this year, AstraZeneca has announced that Susan Galbraith will now lead its oncology R&D from initial discovery through late-stage development.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.
Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
